Saturday, April 20, 2024
Cognivia, an innovative AI company revolutionizing pharmaceutical and biotech clinical research with cutting-edge AI-ML algorithms, proudly announces a significant investment milestone. Vesalius Biocapital IV, SFPIM, and WE have committed to supporting Cognivia's mission to "quantify the power of the mind" in optimizing and accelerating drug development programs through strategic investments. This capital injection will empower Cognivia to deploy predictive clinical study solutions that unravel relationships between patient characteristics and behavior, thus expediting the development of innovative treatments globally.
Cognivia's solutions target critical areas historically challenging in drug development, such as placebo response and treatment adherence in clinical trials. Pioneering in quantitatively understanding patients as individuals, Cognivia integrates these insights into clinical trial data analysis and patient engagement strategies. For instance, its Placebell™ solution employs predictive algorithms to mitigate the placebo response's negative impact, enhancing the research potency of clinical trials and ultimately improving their success rates while reducing time and costs. Compl-AI predicts patient noncompliance and dropout risks during clinical trials, enhancing and personalizing patient engagement strategies.
The raised capital will accelerate Cognivia's efforts to bring its pioneering solutions to market and establish a robust presence in the United States. Cognivia aims to foster better cooperation in business or R&D by expanding its team and establishing a US subsidiary. In the short term, it plans to further develop its network through strategic partnerships, enhance its advisory board, and build teams in both the US and the EU. This strategic move aligns with Cognivia's goal of becoming a leading partner to pharmaceutical and biotech companies, enabling them to develop effective treatments for unmet patient needs.
In the latest funding round, Cognivia proudly welcomes support from three esteemed investors: Vesalius Biocapital IV, a Luxembourg-based venture capital fund focused on HealthTech and biopharma investments; SFPIM, a Belgian sovereign wealth fund providing strategic management and financial support to Belgian companies; and WE, contributing to Wallonia's economic development through financing and sectoral support.
"We are thrilled to introduce Cognivia as the inaugural investment of our IV Fund, which focuses on HealthTech and Biopharma companies driving healthcare-transforming innovation. We anticipate fruitful cooperation throughout its commercialization and growth phases," says Olivier Houben, partner at Vesalius Biocapital.
"Cognivia's alliance with Vesalius Biocapital IV, SFPIM, and WE marks a pivotal moment in our quest to transform the industry through a unique blend of industry experience and advanced AI," comments Dominique Demolle, CEO/Co-Founder of Cognivia. "With this investment and upcoming additions to our team and advisory board, we're poised to accelerate our efforts, delivering disruptive approaches that enable informed, data-driven decisions, and ultimately improving outcomes for patients and stakeholders worldwide."
Source: prnewswire.com
